A Patient’s Guide to Clinical Trials
En Español | En Français
NIH Clinical Research Trials and You
Guidance regarding HIV anti-retroviral treatment in developing countries
Policy on Research Involving Human Subjects
The study is testing the safety of a vaccine for herpes simplex virus-2 (HSV-2). In the United States, HSV-2 affects approximately 16 percent of persons aged 14 to 49. HSV-2 genital infection increases the risk of getting HIV or giving it to someone else. This virus can cause severe disease in people with immature or compromised immune systems. No vaccine is currently available.
You may be eligible if you:
Participants will be assigned to one of three groups: (1) people who have been infected with HSV-1 and HSV-2, (2) people who have been infected only with HSV-1, and (3) people who have not been infected with either HSV-1 or HSV-2.
To determine if you are eligible to participate, you will need to visit the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland, for two screening visits. Eligible participants will receive three vaccine injections over six months. Doctors will continue to monitor participants’ responses to the study vaccine for six months following the last injection.
The study is being conducted at the Warren Grant Magnuson Clinical Center (Building 10) at NIH. The NIH campus is accessible by car and public transportation.
There is no charge to participate in this research study. All study-related medical care and procedures are provided free of charge.
Yes, you will be compensated for your participation in the study.
If you are interested in volunteering for this study, go to the study’s confidential online questionnaire or contact:
Office of Patient Recruitment, NIH Clinical Center
Toll free: 1-800-411-1222 (reference 13-I-0172)
TTY: 1-866-411-1010 Se habla español
Office hours: 8 a.m.-3:30 p.m. ET
To learn more about this study (trial ID: NCT01915212), visit clinicaltrials.gov and read some frequently asked questions.
Last Updated September 04, 2013
Last Reviewed September 04, 2013